NewAmsterdam Pharma (NAMS) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of NewAmsterdam Pharma (NASDAQ: NAMS) in the last few weeks:

• 11/5/2026 – NewAmsterdam Pharma had its price target lowered by Needham & Company LLC from $48.00 to $46.00. They now have a “buy” rating on the stock.
• 11/1/2026 – NewAmsterdam Pharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/24/2026 – NewAmsterdam Pharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/15/2026 – NewAmsterdam Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/5/2026 – NewAmsterdam Pharma had its price target lowered by Royal Bank Of Canada from $50.00 to $42.00. They now have an “outperform” rating on the stock.
• 9/8/2026 – NewAmsterdam Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $52.00 price target on the stock.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded down $2.04 during midday trading on Thursday, hitting $18.89. 1,560,714 shares of the stock were exchanged, compared to its average volume of 1,175,335. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -8.75 and a beta of 0.15. The business’s 50-day moving average price is $22.43 and its 200 day moving average price is $29.65. NewAmsterdam Pharma Company N.V. has a 12 month low of $18.86 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.33. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The company had revenue of $19.16 million during the quarter, compared to the consensus estimate of $8.82 million. As a group, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, insider Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, August 24th. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the transaction, the insider owned 69,302 shares in the company, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael H. Davidson acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of $22.65 per share, with a total value of $226,500.00. Following the completion of the acquisition, the chief executive officer directly owned 792,923 shares of the company’s stock, valued at $17,959,705.95. This trade represents a 1.28% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders sold 176,846 shares of company stock worth $4,661,919. 12.74% of the stock is currently owned by company insiders.

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.